Anaptysbio (ANAB) Interest Coverage Ratio (2016 - 2026)
Anaptysbio's (ANAB) quarterly Interest Coverage Ratio came in at 1.66 in Q1 2026, down 9.27% YoY from 1.83 in Q1 2025, and down 41.47% on a QoQ basis from 1.18 in Q4 2025.
Anaptysbio (ANAB) Interest Coverage Ratio (2016 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 11 years of Interest Coverage Ratio data on file, last reported at 1.66 in Q1 2026.
- Quarterly Interest Coverage Ratio fell 9.27% year-over-year to 1.66 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1.69 (up 199.49% YoY) and the FY2025 annual result came in at 0.27, up 143.23% from the prior year.
- Interest Coverage Ratio fell to 1.66 in Q1 2026, from 1.18 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 23.63 in Q4 2023 to a low of 44.47 in Q4 2022.
- A 5-year average of 2.87 and a median of 1.52 in 2025 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio plunged 5411.97% — and 2025, when it jumped 233.56%.
- Tracing ANAB's Interest Coverage Ratio over 5 years: stood at 44.47 in 2022, then jumped by 153.14% to 23.63 in 2023, then slumped by 100.97% to 0.23 in 2024, then tumbled by 412.04% to 1.18 in 2025, then sank by 41.47% to 1.66 in 2026.
- The last three Interest Coverage Ratio figures came in at 1.66 (Q1 2026), 1.18 (Q4 2025), and 0.51 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | -1.66 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.66 |
| Dec 31, 2025 | -1.18 |
| Sep 30, 2025 | 0.51 |
| Jun 30, 2025 | -1.33 |
| Mar 31, 2025 | -1.52 |
| Dec 31, 2024 | -0.23 |
| Sep 30, 2024 | -0.38 |
| Jun 30, 2024 | -2.06 |
| Mar 31, 2024 | -2.09 |
| Dec 31, 2023 | 23.63 |
| Sep 30, 2023 | -1.76 |
| Jun 30, 2023 | -9.06 |
| Mar 31, 2023 | -1.96 |
| Dec 31, 2022 | -44.47 |
| Sep 30, 2022 | -2.89 |
| Jun 30, 2022 | -1.14 |
| Mar 31, 2022 | -1.27 |
| Dec 31, 2021 | -164.85 |
| Sep 30, 2021 | -0.25 |
| Jun 30, 2021 | -0.02 |